Swan Capital LLC Roivant Sciences Ltd. Transaction History
Swan Capital LLC
- $205 Billion
- Q4 2024
A detailed history of Swan Capital LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Swan Capital LLC holds 90 shares of ROIV stock, worth $957. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90Holding current value
$957% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
332Shares Held
505MCall Options Held
573KPut Options Held
739K-
Qvt Financial LP New York, NY65.8MShares$700 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$660 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$509 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$469 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$376 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.49B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...